系统性红斑狼疮患者体内的抗血清淀粉样蛋白P成分抗体与疾病活动度相关。
Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity.
作者信息
Zandman-Goddard G, Blank M, Langevitz P, Slutsky L, Pras M, Levy Y, Shovman O, Witte T, Doria A, Rovensky J, Shoenfeld Y
机构信息
Centre for Autoimmune Diseases and Department of Medicine B, Sheba Medical Centre, Tel Hashomer, Israel 52621.
出版信息
Ann Rheum Dis. 2005 Dec;64(12):1698-702. doi: 10.1136/ard.2005.035832. Epub 2005 Jul 13.
OBJECTIVE
To determine the presence of raised titres of anti-serum amyloid P component (SAP) antibodies in patients with systemic lupus erythematosus (SLE) and to evaluate their correlation with clinical disease by the SLEDAI and clinical manifestations.
METHODS
452 samples were screened for raised anti-SAP antibody titres by an ELISA. Clinical measures and SLEDAI scores were independently reviewed from medical records. 21 serial samples from 7 patients with SLE were assessed for a change in anti-SAP antibody titres after treatment.
RESULTS
Raised anti-SAP antibody titres were detected in 145/328 (44%) SLE samples. In 112 randomly selected samples, 69/112 (62%) patients had raised anti-SAP antibodies and anti-dsDNA antibody titres, whereas only 32/112 (28%) had raised anti-dsDNA antibody titres without raised anti-SAP antibody titres. The mean titre of anti-SAP antibodies in patients with active disease was higher than in patients with inactive disease and controls. SLEDAI scores, assessed in 54 patients, were raised in 26/31 (84%) patients with raised anti-SAP antibody titres. A SLEDAI score >or=8 was found in 16/31 (52%) patients with raised anti-SAP antibody titres but in only 5/23 (22%) patients without raised titres. No specific pattern of disease was detected in patients with or without raised titres of anti-SAP antibodies. Serial sampling from patients with active SLE and raised anti-SAP antibody titres showed that anti-SAP antibody titres decreased after treatment and correlated with clinical improvement.
CONCLUSION
Raised anti-SAP antibody titres detected in patients with SLE correlate with disease activity and decrease with improvement of clinical disease, and thus may serve as an additional prognostic marker.
目的
确定系统性红斑狼疮（SLE）患者中抗血清淀粉样蛋白P成分（SAP）抗体滴度升高的情况，并通过SLE疾病活动指数（SLEDAI）和临床表现评估其与临床疾病的相关性。
方法
采用酶联免疫吸附测定（ELISA）法对452份样本进行抗SAP抗体滴度升高的筛查。从病历中独立回顾临床指标和SLEDAI评分。对7例SLE患者的21份连续样本进行治疗后抗SAP抗体滴度变化的评估。
结果
在328份SLE样本中，145份（44%）检测到抗SAP抗体滴度升高。在112份随机选择的样本中，69/112（62%）例患者抗SAP抗体和抗双链DNA（dsDNA）抗体滴度升高，而只有32/112（28%）例患者抗dsDNA抗体滴度升高但抗SAP抗体滴度未升高。活动期疾病患者的抗SAP抗体平均滴度高于非活动期疾病患者和对照组。在54例患者中评估SLEDAI评分，31例抗SAP抗体滴度升高的患者中有26例（84%）SLEDAI评分升高。抗SAP抗体滴度升高的31例患者中有16例（52%）SLEDAI评分≥8，而抗SAP抗体滴度未升高的23例患者中只有5例（22%）SLEDAI评分≥8。抗SAP抗体滴度升高或未升高的患者均未检测到特定的疾病模式。对活动期SLE且抗SAP抗体滴度升高的患者进行连续采样显示，治疗后抗SAP抗体滴度下降且与临床改善相关。
结论
SLE患者中检测到的抗SAP抗体滴度升高与疾病活动相关，且随临床疾病改善而下降，因此可能作为一种额外的预后标志物。
Zotero 插件